The 16,17-Double Bond Is Needed for Irreversible Inhibition of Human Cytochrome P45017α by Abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and Related Steroidal Inhibitors
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Abiraterone (17-(3-pyridyl)androsta-5,16-dien-3beta-ol, 1) is a potent inhibitor (IC50 4 nM for hydroxylase) of human cytochrome P45017alpha. To assist in studies of the role of the 16,17-double bond in its mechanism of action, the novel 17alpha-(4-pyridyl)androst-5-en-3beta-ol (5) and 17beta-(3-pyridyl)-16,17alpha-epoxy-5alpha-androst-3beta-ol (6) were synthesized. 3beta-Acetoxyetienic acid was converted in three steps into 5 via photolysis of the thiohydroxamic ester 8. Oxidation of an appropriate 16,17-unsaturated precursor (21) with CrO3-pyridine afforded the acetate (23) of 6. Inhibition of the enzyme by 1, the similarly potent 5,6-reduced analogue 19 (IC50 5 nM), and the 4, 16-dien-3-one 26 (IC50 3 nM) and by the less potent (IC50 13 nM) 3,5, 16-triene 25 is slow to occur but is enhanced by preincubation of the inhibitor with the enzyme. Inhibition following preincubation with these compounds is not lessened by dialysis for 24 h, implying irreversible binding to the enzyme. In contrast under these conditions the still potent (IC50 27 nM) 17alpha-(4-pyridyl)androst-5-en-3beta-ol (5) showed partial reversal after 5 h of dialysis and complete reversal of inhibition after 24 h. This behavior was also shown by the less potent 16,17-reduced 3-pyridyl compounds 3 and 24. Further, in contrast to the compounds (1, 19, 25, 26) with the 16,17-double bond, the inhibition of the enzymic reaction was not enhanced by preincubation either with 5 or with the 17beta-pyridyl analogues 3, 4, and 24 which also lack this structural feature. The results show that the 16,17-double bond is necessary for irreversible binding of these pyridyl steroids to cytochrome P45017alpha. However oxidation to an epoxide is probably not involved since epoxide 6 was only a moderately potent inhibitor (IC50 260 nM).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abiraterone acetate, a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17 (CYP17), a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [14]
Citations
Cites
Radical chemistry associated with the thiocarbonyl group
Crich, D., & Quintero, L. (1989) · Chemical Reviews · doi:10.1021/cr00097a001 · Cited by 496
Recent Developments of Free-Radical Substitutions of Heteroaromatic Bases
Minisci, F., Vismara, E., & Fontana, F. (1989) · HETEROCYCLES · doi:10.3987/rev-88-sr1 · Cited by 452
Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a022 · Cited by 379
Self-citationPharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase)
Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90131-7 · Cited by 253
Self-citationWong, C. H., & Matos, J. R. (1985) · The Journal of Organic Chemistry · doi:10.1021/jo00211a046 · Cited by 69
Angelastro, M. R., Laughlin, M. E., Schatzman, G. L., Bey, P., & Blohm, T. R. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)90854-1 · Cited by 46
Rollin, P. (1986) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)84938-2 · Cited by 40
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors
Barrie, S. E., Haynes, B. P., Potter, G. A., Chan, F. C. Y., Goddard, P. M., Dowsett, M., & Jarman, M. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00225-7 · Cited by 37
Self-citationKurihara, T., Sugizaki, M., Kime, I., Wada, M., & Mitsunobu, O. (1981) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.54.2107 · Cited by 35
Alcohol inversion of 17β-steroids
Dodge, J. A., & Lugar, C. W. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00559-c · Cited by 33
Research works printed but not linked: 9
- Rowlands M. G., 1996, J. Med. Chem., 38, 4197
- Chan F. C. Y., 1996, J. Med. Chem., 39, 3323
- Burke D. F. Ph.D., 1994, University of London
- Sato T., 1995, J. Org. Chem., 60, 2629
- Garreg P., 1982, J. Chem Soc., Perkin Trans. 1, 681, 683
- Barton D. H. R., 1986, Tetrahedron Lett., 27, 1330
- Catagnino E., 1986, Tetrahedron Lett., 27, 6338
- Bo T., 1996, Synthesis, 324, 326
- Pearson A. J., 1985, J. Chem. Soc., Perkin Trans. 1, 267, 273
Cited by
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
“Adverse event leading to death* 20 (4) 12 (2) Adverse event of grade 1–4 in ≥15% of patients in either group Fatigue 212 (39) 185 (34) Back pain 173 (32) 173 (32) Arthralgia 154 (28) 129 (24) Nausea 120 (22) 118 (22) Constipation 125 (23) 103 (19) Hot flush 121 (22) 98 (18) Diarrhea 117 (22) 96 (18) Bone pain 106 (20)…”
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
In silico methods and tools for drug discovery
Shaker, B., Ahmad, S., Lee, J., Jung, C., & Na, D. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104851 · Cited by 607
Minisci reactions: Versatile CH-functionalizations for medicinal chemists
Duncton, M. A. J. (2011) · MedChemComm · doi:10.1039/c1md00134e · Cited by 607
Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
Discovering Anti-Cancer Drugs via Computational Methods
Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 307
“Gefitinib (Muhsin et al., 2003), Erlotinib (Grunwald and Hidalgo, 2003), Sorafenib (Wilhelm et al., 2006), Lapatinib (Wood et al., 2004), Abiraterone (Jarman et al., 1998), Crizotinib (Butrynski et al., 2010) are all approved drugs that have been discovered based on computational drug methods.”
BackgroundAttard, G., Reid, A. H. M., Auchus, R. J., Hughes, B. A., Cassidy, A. M., Thompson, E., Oommen, N. B., Folkerd, E., Dowsett, M., Arlt, W., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2189 · Cited by 282
Inhibition of Cytochrome P450 Enzymes
Correia, M. A., & Hollenberg, P. F. (2015) · Cytochrome P450 · doi:10.1007/978-3-319-12108-6_5 · Cited by 257
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
“To prevent this, AA is coadministered with prednisone 5 mg twice daily [8–10].”
BackgroundAttard, G., Belldegrun, A. S., & De Bono, J. S. (2005) · BJU International · doi:10.1111/j.1464-410x.2005.05821.x · Cited by 207
Ferraldeschi, R., Welti, J., Luo, J., Attard, G., & de Bono, J. S. (2015) · Oncogene · doi:10.1038/onc.2014.115 · Cited by 192
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents
Yin, L., & Hu, Q. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2013.274 · Cited by 172
The changing therapeutic landscape of castration-resistant prostate cancer
Yap, T. A., Zivi, A., Omlin, A. G., & Bono, J. S. D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.117 · Cited by 156
“CYP17 inhibitors Abiraterone Abiraterone acetate is a small-molecule inhibitor of cytochrome P450 (CYP)17”
BackgroundCastration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
Sridhar, S. S., Freedland, S. J., Gleave, M. E., Higano, C. S., Mulders, P., Parker, C. C., Sartor, O. A., & Fred Saad, C. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.008 · Cited by 152
Visible light-promoted C–H functionalization of ethers and electron-deficient arenes
Devari, S., & Shah, B. A. (2015) · Chemical Communications · doi:10.1039/c5cc08817h · Cited by 129
Non‐Competitive Inhibition by Active Site Binders
Blat, Y. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.00972.x · Cited by 127
“This was indeed demonstrated for the cyclo-oxygenase 2 and CYP17 lyase inhibitors discussed previously (18,19).”
BackgroundCancer wars: natural products strike back
Basmadjian, C., Zhao, Q., Bentouhami, E., Djehal, A., Nebigil, C. G., Johnson, R. A., Serova, M., Gramont, A. D. E., Faivre, S. J., Raymond, É., et al. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00020 · Cited by 142
“…by Jarman et al. at the Institute of Cancer Research in Sutton (UK) based on the hypothesis that the nitrogen lone pair of a pyridyl moiety linked to the steroid skeleton would coordinate with the iron atom of the heme cofactor in the active site of CYP17 (Potter et al., 1995; Jarman et al., 1998).”
BackgroundCYP17 inhibition as a hormonal strategy for prostate cancer
Reid, A. H. M., Attard, G., Barrie, E., & Bono, J. S. D. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1237 · Cited by 119
“Important features of abiraterone are the 3-pyridyl substituent and the C16–C17 double bond, which together place the pyridyl nitrogen in the correct orientation for binding to the heme iron of CYP17”
BackgroundCastration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
Amaral, T. M. S., Macedo, D., Fernandes, I., & Costa, L. (2012) · Prostate Cancer · doi:10.1155/2012/327253 · Cited by 133
Qu, F., Xie, W., Nakabayashi, M., Zhang, H., Jeong, S. H., Wang, X., Komura, K., Sweeney, C. J., Sartor, O. A., Lee, G. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1070 · Cited by 116
“Abiraterone acetate is an inhibitor of CYP17A1 that blocks androgen production (13, 14).”
Targeting CYP17: established and novel approaches in prostate cancer
Yap, T. A., Carden, C. P., Attard, G., & Bono, J. S. D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.004 · Cited by 110
“The double bond in the 16,17-position of the steroidal skeleton is essential for the irreversible inhibition of CYP17 [51].”
BackgroundHaidar, S., Ehmer, P. B., Barassin, S., Batzl‐Hartmann, C., & Hartmann, R. W. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00070-0 · Cited by 103
Application of computational methods for anticancer drug discovery, design, and optimization
Prada‐Gracia, D., Huerta‐Yépez, S., & Moreno‐Vargas, L. M. (2016) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2016.10.006 · Cited by 119
Abiraterone acetate in the treatment of prostate cancer
Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.067 · Cited by 112
Steroidogenic cytochrome P450 17A1 structure and function
Burris‐Hiday, S. D., & Scott, E. E. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111261 · Cited by 100
Yamaoka, M., Hara, T., & Kusaka, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0255 · Cited by 92
Zhang, J., & Che, C. (2005) · Chemistry - A European Journal · doi:10.1002/chem.200401008 · Cited by 83
Smith, R. L., Liu, M., Liby, T. A., Bayani, N., Bucher, E., Chiotti, K., Derrick, D. S., Chauchereau, A., Heiser, L. M., Alumkal, J. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78798-x · Cited by 91
Hu, Q., Yin, L., & Hartmann, R. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3004637 · Cited by 69
Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
Bryce, A. H., & Ryan, C. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.275 · Cited by 71
Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers
Smith, H. J., Nicholls, P. J., Simons, C., & Lain, R. L. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.5.789 · Cited by 75
“Inhibition of P450 17 by abiraterone after preincubation is not decreased by dialysis implying irreversible binding to the enzyme confirmed by removal of the 16,17-double bond which led to complete reversal of inhibition [210].”
BackgroundInhibition of Cytochrome P450 Enzymes
Correia, M. A., & de Montellano, P. R. O. (2007) · Springer eBooks · doi:10.1007/0-387-27447-2_7 · Cited by 72
Michalak, M., Michalak, K., & Wicha, J. (2017) · Natural Product Reports · doi:10.1039/c6np00107f · Cited by 62
Schweizer, M. T., & Antonarakis, E. S. (2012) · Therapeutic Advances in Urology · doi:10.1177/1756287212452196 · Cited by 67
“It was found that the key molecular feature that provided potent inhibition of CYP17 was the 16,17 double bond and http://tau.sagepub.com 169 3-pyridyl substitution [Bryce and Ryan, 2012; Jarman et al. 1998].”
BackgroundStrajhar, P., Tonoli, D., Jeanneret, F., Imhof, R. M., Malagnino, V., Patt, M., Kratschmar, D. V., Boccard, J., Rudaz, S. L., & Odermatt, A. (2017) · Toxicology · doi:10.1016/j.tox.2017.02.010 · Cited by 62
Inhibition of CYP 17, a New Strategy for the Treatment of Prostate Cancer
Hartmann, R. W., Ehmer, P. B., Haidar, S., Hector, M., Jose, J., Klein, C. D. P., Seidel, S. B., Sergejew, T. F., Wachall, B. G., Wächter, G. A., et al. (2002) · Archiv der Pharmazie · doi:10.1002/1521-4184(200204)335:4<119::aid-ardp119>3.0.co;2-# · Cited by 65
Salvador, J. A. R., Pinto, R. M. A., & Silvestre, S. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.04.006 · Cited by 82
Hu, Q., Negri, M., Jahn‐Hoffmann, K., Zhuang, Y., Ölgen, S., Bartels, M., Müller‐Vieira, U., Lauterbach, T., & Hartmann, R. W. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.011 · Cited by 60
Sonpavde, G., Attard, G., Bellmunt, J., Mason, M. D., Malavaud, B. A., TOMBAL, B. F., & Sternberg, C. N. (2011) · European Urology · doi:10.1016/j.eururo.2011.04.032 · Cited by 62
“The 16,17-double bond is necessary for its irreversible binding to CYP17, and the 3-pyridyl substitution results in its being 10–30 times as potent in the selective inhibition of CYP17 compared to ketoconazole [34,35].”
BackgroundInhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Baston, E., & Leroux, F. R. (2007) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489207779561453 · Cited by 53
Application of computational methods for anticancer drug discovery, design, and optimization
Prada‐Gracia, D., Huerta‐Yépez, S., & Moreno‐Vargas, L. M. (2016) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.1016/j.bmhime.2017.11.040 · Cited by 58
“…et al. (2004)92 Abiraterone Metastatic castration-resistant prostate cancer or hormone-refractory prostate cancer Androgen synthesis inhibitor 2011 Jarman et al. (1998)96 O’Donnell et al. (2004)97 Jagusch et al. (2008)98 Crizotinib NSCLC ALK inhibitor 2011 Butrynski et al. (2010)99 Rodig et al.…”
Spade, D. J., Hall, S. J., Saffarini, C. M., Huse, S. M., McDonnell, E. V., & Boekelheide, K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft266 · Cited by 50
“CYP17A1 inhibition by abiraterone has been well characterized (Jarman et al., 1998).”
BackgroundEmerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance
Rahman, M. M., Islam, M. R., Rahman, F., Rahaman, M. S., Khan, M. S., Abrar, S., Ray, T. K., Uddin, M. B., Kali, M. S. K., Dua, K., et al. (2022) · Bioengineering · doi:10.3390/bioengineering9080335 · Cited by 52
Drug–Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization
Gan, J., Zhang, H., & Humphreys, W. G. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00274 · Cited by 46
Novel P45017α inhibitors: 17-(2′-oxazolyl)- and 17-(2′-thiazolyl)-androstene derivatives
Zhu, N., Ling, Y., Lei, X., Handratta, V. D., & Brodie, A. M. H. (2003) · Steroids · doi:10.1016/s0039-128x(03)00082-5 · Cited by 42
Guo, C., Yeh, S., Niu, Y., Li, G., Zheng, J., Li, L., & Chang, C. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.022 · Cited by 42
Neighboring group participation
Woelfling, J., Hackler, L., Mernyák, E., Schneider, G., Tóth, I., Szécsi, M., Julesz, J., Sohár, P., & Csámpai, A. (2004) · Steroids · doi:10.1016/j.steroids.2004.04.003 · Cited by 41
Maity, S. N., Titus, M. A., Gyftaki, R., Wu, G., Lu, J.-F., Ramachandran, S., Li-Ning-Tapia, E. M., Logothetis, C. J., Araujo, J. C., & Efstathiou, E. (2016) · Scientific Reports · doi:10.1038/srep35354 · Cited by 42
“Abiraterone acetate (AA; Zytiga) in combination with prednisone is approved for treatment of CRPC. AA specifically and irreversibly inhibits both CYP17A1 hydroxylase and lyase 5 .”
Banday, A. H., Giri, A. K., Parveen, R., & Bashir, N. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.009 · Cited by 37
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
Wadosky, K. M., & Koochekpour, S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14090 · Cited by 44
“Pre-clinical studies have shown that not only does galeterone inhibit CYP17 [81], but also inhibits AR transcriptional activity [81, 82] and promotes the proteasomal degradation of both AR and its ligand-independent variants AR-V7 and ARv567es [83].”
BackgroundInfluentialHalim, S. A., Jabeen, S., Khan, A., & Al‐Harrasi, A. (2021) · Pharmaceuticals · doi:10.3390/ph14050482 · Cited by 42
Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis
Zhu, X., & Wu, S. (2019) · Clinical Hypertension · doi:10.1186/s40885-019-0110-3 · Cited by 37
Kovács, D., Kádár, Z., Mótyán, G., Schneider, G., Woelfling, J., Zupkó, I., & Frank, É. (2012) · Steroids · doi:10.1016/j.steroids.2012.05.003 · Cited by 35
Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00031-x · Cited by 39
Single‐dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment
Marbury, T. C., Lawitz, E., Stonerock, R., Gonzalez, M., Jiao, J. J., Breeding, J., Haqq, C. M., Verboven, P., Stieltjes, H., Yu, M. K., et al. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.253 · Cited by 33
“Abiraterone acetate is a prodrug of abiraterone, a selective irreversible inhibitor of cytochrome P 17a‐hydroxylase/ C17, 20‐lyase (CYP17) enzyme that plays a key role in the production of androgens in the testes, adrenal glands, and intratumorally.(1,2) More than 80 countries across the globe have approved abirateron…”
BackgroundWoelfling, J., Oravecz, É. A., Ondré, D., Mernyák, E., Schneider, G., Tóth, I., Szécsi, M., & Julesz, J. (2006) · Steroids · doi:10.1016/j.steroids.2006.05.011 · Cited by 32
Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
Hara, T., Kouno, J., Kaku, T., Takeuchi, T., Kusaka, M., Tasaka, A., & Yamaoka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.10.020 · Cited by 34
Mark, M. T., Klingbiel, D., Mey, U., Winterhalder, R., Rothermundt, C. A., Gillessen, S., von Moos, R., Pollak, M., Manetsch, G., Strebel, R. T., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.12.009 · Cited by 33
Hu, J., Aprikian, A. G., Vanhuyse, M., & Dragomir, A. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.08.009 · Cited by 35
Alyamani, M., Li, Z., Upadhyay, S. K., Anderson, D. J., Auchus, R. J., & Sharifi, N. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.002 · Cited by 33
Conjugate base catalysed one-pot synthesis of pyrazoles from β-formyl enamides
Saikia, A. K., Barthakur, M. G., Borthakur, M., Saikia, C. J., Bora, U., & Boruah, R. C. (2005) · Tetrahedron Letters · doi:10.1016/j.tetlet.2005.10.145 · Cited by 31
Ondré, D., Woelfling, J., Tóth, I., Szécsi, M., Julesz, J., & Schneider, G. (2009) · Steroids · doi:10.1016/j.steroids.2009.08.001 · Cited by 30
Synthesis of novel C17 steroidal carbamates
Moreira, V. M., Vasaitis, T. S., Guo, Z., Njar, V. C. O., & Salvador, J. A. R. (2008) · Steroids · doi:10.1016/j.steroids.2008.05.010 · Cited by 32
Iványi, Z., Woelfling, J., Görbe, T., Szécsi, M., Wittmann, T., & Schneider, G. (2010) · Steroids · doi:10.1016/j.steroids.2010.02.013 · Cited by 30
Fiandalo, M. V., Wilton, J. H., & Mohler, J. L. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8780 · Cited by 37
“One potent inhibitor against CYP17A1 is the new FDA-approved drug, abiraterone [31, 45-48].”
BackgroundSharma, U., Bora, U., Boruah, R. C., & Sandhu, J. S. (2002) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)02049-4 · Cited by 30
Tucci, M., Caffo, O., Buttigliero, C., Cavaliere, C., D’Aniello, C., Maïo, M. D., Kinspergher, S., Maines, F., Rizzo, M., Rossetti, S., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.01.002 · Cited by 31
Abiraterone Acetate: A Promising Drug for the Treatment of Castration-Resistant Prostate Cancer
Agarwal, N., Hutson, T. E., Vogelzang, N. J., & Sonpavde, G. (2010) · Future Oncology · doi:10.2217/fon.10.48 · Cited by 31
Frasinyuk, M. S., Mrug, G. P., Bondarenko, S. P., Khilya, V. P., Sviripa, V. M., Syrotchuk, O. A., Zhang, W., Cai, X., Fiandalo, M. V., Mohler, J. L., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600008 · Cited by 32
Shingate, B. B., Hazra, B. G., Salunke, D. B., Pore, V. S., Shirazi, F., & Deshpande, M. V. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.032 · Cited by 27
Targeting sex steroid biosynthesis for breast and prostate cancer therapy
POUTANEN, M. H., Thulin, M. H., & Härkönen, P. L. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00609-y · Cited by 32
Cheong, E. J. Y., Nair, P. C., Neo, R. W. Y., Ho, T. T., Lin, F., Chiong, E., Esuvaranathan, K., Fan, H., Szmulewitz, R. Z., Peer, C. J., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265868 · Cited by 29
“Furthermore, abiraterone was suggested to be a slow-binding inhibitor with enhanced inhibition upon preincubation with CYP17A1 (Jarman et al., 1998).”
BackgroundRecent Trends in Computer-aided Drug Design for Anti-cancer Drug Discovery
Razia, I. T., Kanwal, A., Riaz, H. F., Malik, A., Ahsan, M., Khan, M. S., Raza, A., Sabir, S., Sajid, Z., Khan, M. F., et al. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266258467231107102643 · Cited by 30
Mortezavi, A., Salemi, S., Kranzbühler, B., Gross, O., Sulser, T., Simon, H., & Eberli, D. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2385-5 · Cited by 26
Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer.
Recine, F., & Sternberg, C. N. (2015) · PubMed Central · doi:10.3978/j.issn.2223-4683.2015.04.11 · Cited by 36
“Abiraterone is a potent and specific steroidogenic inhibitor that irreversibly inhibits the enzyme CYP17A1, the most important enzyme that catalyzes two essential steroidogenic reactions, the 17α-hydroxylase and 17,20-lyase responsible for converting pregnenolone to 17-OH-pregnenolone and subsequently 17-OH-pregnenolo…”
BackgroundNew Therapeutics to Treat Castrate‐Resistant Prostate Cancer
Acar, Ö., Esen, T., & Lack, N. A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/379641 · Cited by 31
Guarna, A., Occhiato, E. G., Machetti, F., & Giacomelli, V. (1999) · The Journal of Organic Chemistry · doi:10.1021/jo990373m · Cited by 24
In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin
Aventurado, C. A., Billones, J. B., Vasquez, R. D., & Castillo, A. L. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s271952 · Cited by 26
Yuan, L., Zhao, J., Zhao, S., Dong, T., Dong, R., Liu, D., Ma, E., & Li, Y. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109811 · Cited by 25
Caffo, O., Palermo, A., Veccia, A., Maines, F., Chierichetti, F., Berruti, A., & Galligioni, E. (2013) · Urology · doi:10.1016/j.urology.2013.07.029 · Cited by 22
Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis
Zhu, X., & Wu, S. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1670203 · Cited by 22
Patt, M., Beck, K. R., Marco, T. D., Jäger, M.-C., González‐Ruiz, V., Boccard, J., Rudaz, S. L., Hartmann, R. W., Salah, M., van Koppen, C. J., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113781 · Cited by 28
Synthesis of D-Ring Annulated Pyridosteroids from β-Formyl Enamides and Their Biological Evaluations
Nongthombam, G. S., Borah, K., Muinao, T., Silla, Y., Pal, M., Boruah, H. P. D., & Boruah, R. C. (2018) · ACS Combinatorial Science · doi:10.1021/acscombsci.8b00140 · Cited by 21
Szabó, N., Ajduković, J. J., Djurendić, E. A., Sakač, M. N., Ignáth, I., Gardi, J., Mahmoud, G., Klisurić, O. R., Jovanović-Šanta, S., Gaši, K. M. P., et al. (2015) · Acta Biologica Hungarica · doi:10.1556/abiol.66.2015.1.4 · Cited by 20
Caffo, O., Giorgi, U. D., Fratino, L., Re, G. L., Basso, U., D’Angelo, A., Donini, M., Verderame, F., Ratta, R., Procopio, G., et al. (2014) · British Journal of Urology · doi:10.1111/bju.12857 · Cited by 19
Kiss, M. A., Peřina, M., Bazgier, V., May, N. V., Baji, Á., Jorda, R., & Frank, É. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105904 · Cited by 19
The development of abiraterone acetate for castration-resistant prostate cancer
Grist, E., & Attard, G. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.03.021 · Cited by 24
“Important features of abiraterone include the pyridyl ring at C17 (the 2-pyridyl and 4-pyridal analogues are less potent) and the C16, 17 double bond [11].”
BackgroundGravanis, I., Sancho-López, A., Hemmings, R. J., Jiménez, J. C., García‐Carbonero, R., Gallego, I. G., Giménez, E. V., O’Connor, D. J., Giuliani, R., Salmonson, T., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0092 · Cited by 22
Elshazly, A. M., & Gewirtz, D. A. (2023) · Cancers · doi:10.3390/cancers15205029 · Cited by 20
“…in In addition to the antagonism of AR, which mediates the actions of abiraterone in CYP17A1 low-expressing cells (ex: LNCap) [37,38], the primary mode of action for abiraterone is the selective inhibition of androgen biosynthesis via a blockade to 17 α -hydroxylase/C17,20 lyase (CYP17A1) [39].”
BackgroundThe CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer
Capper, C. P., Larios, J. M., Sikora, M. J., Johnson, M. D., & Rae, J. M. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3774-3 · Cited by 22
Ajduković, J. J., Jakimov, D., Rárová, L., Strnad, M., Dzichenka, Y. U., Usanov, S. A., Škorić, D., Jovanović-Šanta, S., & Sakač, M. N. (2021) · RSC Advances · doi:10.1039/d1ra07613b · Cited by 17
Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases
Zustovich, F., & Fabiani, F. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.01.003 · Cited by 17
Splice variants of androgen receptor and prostate cancer
Caffo, O., Maines, F., Veccia, A., Kinspergher, S., & Galligioni, E. (2016) · Oncology Reviews · doi:10.4081/oncol.2016.297 · Cited by 61
Blow, T., Murthy, A., Grover, R., Schwitzer, E., Nanus, D. M., Halpenny, D. F., Plodkowski, A. J., Jones, L. W., & Goncalves, M. D. (2023) · European Urology Open Science · doi:10.1016/j.euros.2023.09.004 · Cited by 17
“For example, abiraterone (ABI) is a 17 a -hydroxylase and 17,20-lyase inhibitor that blocks the early steps of androgen biosynthesis in the testes, adrenal gland, and prostate cancer cells [11].”
BackgroundPrzezdziecka, A., Kurek‐Tyrlik, A., & Wicha, J. (2002) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc20021658 · Cited by 15
Iványi, Z., Szabó, N., Woelfling, J., Szécsi, M., Julesz, J., & Schneider, G. (2012) · Steroids · doi:10.1016/j.steroids.2012.07.001 · Cited by 14
Unraveling Caco-2 cells through functional and transcriptomic assessments
Jeong, Y., Shea, K. I., & Ford, K. A. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105771 · Cited by 14
New treatment options for patients with metastatic castration-resistant prostate cancer
Higano, C. S. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.007 · Cited by 11
Therapeutic management of bone metastasis in prostate cancer: an update
Zustovich, F., & Pastorelli, D. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1241148 · Cited by 14
“20-lyase (CYP17A1), therefore inhibiting androgen synthesis in adrenal glands, testicles, and PCa, the only organs or tissues where this enzyme is expressed [80,81].”
Background
Metadata
- Authors
- Jarman, M., Barrie, S. E., & Llera, J. M.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Jarman, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1998-12-01
- Volume
- 41
- Issue
- 27
- Pages
- 5375-5381
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2110171529
- Cited by
- 151
- References
- 16
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 6 · 2019: 8 · 2018: 5 · 2017: 5 · 2016: 15 · 2015: 9 · 2014: 7 · 2013: 16 · 2012: 11
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- abiraterone, irreversible enzyme inhibition, structure-activity relationship, androgen production
- MeSH terms
- Androstanols, Androstenes, Androstenols, Enzyme Inhibitors, Humans, Kinetics, Male, Pyridines, Steroid 17-alpha-Hydroxylase, Structure-Activity Relationship, Testis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.